

AEGON NV  
Form 6-K  
May 11, 2017  
[Table of Contents](#)

# **Securities and Exchange Commission**

**Washington, D.C. 20549**

## **Form 6-K**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d/16 of**

**the Securities Exchange Act of 1934**

**May 2017**

# **AEGON N.V.**

**Aegonplein 50**

**2591 TV THE HAGUE**

**The Netherlands**

**Table of Contents**

Aegon's condensed consolidated interim financial statements 1Q 2017, dated May 11, 2017, are included as appendix and incorporated herein by reference.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AEGON N.V.

(Registrant)

Date: May 11, 2017

By /s/ J.H.P.M. van Rossum  
J.H.P.M. van Rossum  
Head of Corporate Financial Center

---

**Table of Contents**

---

**Table of Contents**

Condensed Consolidated Interim Financial Statements 1Q 2017

1

[Table of contents](#)

<a href="#"><u>Condensed consolidated income statement</u></a>	<a href="#">2</a>
<a href="#"><u>Condensed consolidated statement of comprehensive income</u></a>	<a href="#">3</a>
<a href="#"><u>Condensed consolidated statement of financial position</u></a>	<a href="#">4</a>
<a href="#"><u>Condensed consolidated statement of changes in equity</u></a>	<a href="#">5</a>
<a href="#"><u>Condensed consolidated cash flow statement</u></a>	<a href="#">6</a>
<a href="#"><u>Notes to the Condensed consolidated interim financial statements</u></a>	<a href="#">7</a>

Unaudited

**Table of Contents**

2	Condensed Consolidated Interim Financial Statements 1Q 2017
---	---

**Condensed consolidated income statement**

<i>EUR millions</i>	Notes	1Q 2017	1Q 2016
Premium income	4	5,710	5,836
Investment income	5	1,863	1,935
Fee and commission income		621	602
Other revenues		1	1
<b>Total revenues</b>		<b>8,196</b>	<b>8,374</b>
Income from reinsurance ceded		751	720
Results from financial transactions	6	6,694	2,050
Other income	7	9	-
<b>Total income</b>		<b>15,650</b>	<b>11,146</b>
Benefits and expenses	8	15,055	10,901
Impairment charges / (reversals)	9	13	40
Interest charges and related fees		93	97
<b>Total charges</b>		<b>15,161</b>	<b>11,039</b>
Share in profit / (loss) of joint ventures		34	31
<b>Income / (loss) before tax</b>		<b>523</b>	<b>138</b>
Income tax (expense) / benefit		(145)	6
<b>Net income / (loss)</b>		<b>378</b>	<b>143</b>
<b>Net income / (loss) attributable to:</b>			
Owners of Aegon N.V.		378	143
Non-controlling interests		-	-
<b>Earnings per share (EUR per share)</b>	16		
Basic earnings per common share		0.17	0.05
Basic earnings per common share B		-	-
Diluted earnings per common share		0.17	0.05
Diluted earnings per common share B		-	-

Unaudited

**Table of Contents**

## Condensed Consolidated Interim Financial Statements 1Q 2017

3

**Condensed consolidated statement of comprehensive income**

<i>EUR millions</i>	1Q 2017	1Q 2016
Net income / (loss)	378	143
<b>Other comprehensive income:</b>		
<b>Items that will not be reclassified to profit or loss:</b>		
Changes in revaluation reserve real estate held for own use	-	(2)
Remeasurements of defined benefit plans	265	(501)
Income tax relating to items that will not be reclassified	(67)	135
<b>Items that may be reclassified subsequently to profit or loss:</b>		
Gains / (losses) on revaluation of available-for-sale investments	467	1,841
Gains / (losses) transferred to the income statement on disposal and impairment of available-for-sale investments	(80)	(30)
Changes in cash flow hedging reserve	4	304
Movement in foreign currency translation and net foreign investment hedging reserve	(218)	(734)
Equity movements of joint ventures	(8)	3
Equity movements of associates	(1)	1
Income tax relating to items that may be reclassified	(116)	(762)
Other	2	6
Other comprehensive income / (loss) for the period	248	261
<b>Total comprehensive income / (loss)</b>	<b>626</b>	<b>405</b>
<b>Total comprehensive income / (loss) attributable to:</b>		
Owners of Aegon N.V.	626	398
Non-controlling interests	-	7

Unaudited

**Table of Contents****4 Condensed Consolidated Interim Financial Statements 1Q 2017****Condensed consolidated statement of financial position**

		Mar. 31, 2017	Dec. 31, 2016
<i>EUR millions</i>	Notes		
<b>Assets</b>			
Cash and cash equivalents		11,037	11,347
Assets held for sale	18	8,866	8,705
Investments	10	155,847	156,813
Investments for account of policyholders	11	206,294	203,610
Derivatives	12	7,676	8,318
Investments in joint ventures		1,648	1,614
Investments in associates		288	270
Reinsurance assets		10,848	11,208
Deferred expenses	14	11,435	11,423
Other assets and receivables		9,675	10,805
Intangible assets	15	1,841	1,820
<b>Total assets</b>		<b>425,455</b>	<b>425,935</b>
<b>Equity and liabilities</b>			
Shareholders' equity		21,505	20,913
Other equity instruments		3,804	3,797
<b>Issued capital and reserves attributable to owners of Aegon N.V.</b>		<b>25,308</b>	<b>24,710</b>
Non-controlling interests		23	23
<b>Group equity</b>		<b>25,332</b>	<b>24,734</b>
Subordinated borrowings		768	767
Trust pass-through securities		152	156
Insurance contracts		117,831	119,569
Insurance contracts for account of policyholders		123,118	120,929
Investment contracts		17,807	19,572
Investment contracts for account of policyholders		85,365	84,774
Derivatives	12	7,987	8,878
Borrowings	17	15,021	13,153
Liabilities held for sale	18	8,976	8,816
Other liabilities		23,098	24,588
<b>Total liabilities</b>		<b>400,123</b>	<b>401,201</b>

<b>Total equity and liabilities</b>	<b>425,455</b>	<b>425,935</b>
-------------------------------------	----------------	----------------

Unaudited



**Table of Contents**

## Condensed Consolidated Interim Financial Statements 1Q 2017

5

**Condensed consolidated statement of changes in equity**

<i>EUR millions</i>	Share capital <sup>1</sup>	Retained earnings	Revaluation reserves	Remeasurement of defined benefit plans	Other reserves	Other equity instruments	Issued capital and reserves	Non-controlling interests	Total
At beginning of year	8,193	7,812	5,381	(1,820)	1,347	3,797	24,710	23	24,734
Net income / (loss) recognized in the income statement	-	378	-	-	-	-	378	-	378
<b>Other comprehensive income:</b>									
<b><i>Items that will not be reclassified to profit or loss:</i></b>									
Remeasurements of defined benefit plans	-	-	-	265	-	-	265	-	265
Income tax relating to items that will not be reclassified	-	-	-	(68)	-	-	(67)	-	(67)
<b><i>Items that may be reclassified subsequently to profit or loss:</i></b>									
Gains / (losses) on revaluation of available-for-sale investments	-	-	467	-	-	-	467	-	467
Gains / (losses) transferred to income statement on disposal and impairment of available-for-sale investments	-	-	(80)	-	-	-	(80)	-	(80)
Changes in cash flow hedging reserve	-	-	4	-	-	-	4	-	4
Movement in foreign currency translation and net	-	-	(49)	10	(179)	-	(218)	-	(218)

foreign investment hedging reserves									
Equity movements of joint ventures	-	-	-	-	(8)	-	(8)	-	(8)
Equity movements of associates	-	-	-	-	(1)	-	(1)	-	(1)
Income tax relating to items that may be reclassified	-	-	(124)	-	8	-	(116)	-	(116)
Other	-	1	-	-	-	-	1	-	2
<b>Total other comprehensive income</b>	-	<b>1</b>	<b>218</b>	<b>208</b>	<b>(180)</b>	-	<b>247</b>	-	<b>248</b>
<b>Total comprehensive income / (loss) for 2017</b>	-	<b>379</b>	<b>218</b>	<b>208</b>	<b>(180)</b>	-	<b>626</b>	-	<b>626</b>
Coupons on non-cumulative subordinated notes	-	(7)	-	-	-	-	(7)	-	(7)
Coupons on perpetual securities	-	(27)	-	-	-	-	(27)	-	(27)
Incentive plans	-	-	-	-	-	6	6	-	6
<b>At end of period</b>	<b>8,193</b>	<b>8,157</b>	<b>5,600</b>	<b>(1,612)</b>	<b>1,167</b>	<b>3,804</b>	<b>25,308</b>	<b>23</b>	<b>25,332</b>

**Three months ended  
March 31, 2016**

At beginning of year	8,387	8,075	6,471	(1,532)	1,283	3,800	26,485	9	26,494
Net income / (loss) recognized in the income statement	-	143	-	-	-	-	143	-	143

**Other comprehensive income:**

**Items that will not be reclassified to profit or loss:**

Changes in revaluation reserve real estate held for own use	-	-	(2)	-	-	-	(2)	-	(2)
Remeasurements of defined benefit plans	-	-	-	(501)	-	-	(501)	-	(501)
Income tax relating to items that will not be reclassified	-	-	-	136	-	-	135	-	135

**Items that may be reclassified subsequently to profit or loss:**

Gains / (losses) on revaluation of available-for-sale investments	-	-	1,841	-	-	-	1,841	-	1,841
Gains / (losses) transferred to income statement on disposal and impairment of	-	-	(30)	-	-	-	(30)	-	(30)

available-for-sale investments									
Changes in cash flow									
hedging reserve	-	-	304	-	-	-	304	-	304
Movement in foreign									
currency translation and net									
foreign investment hedging									
reserves	-	-	-	53	(787)	-	(734)	-	(734)
Equity movements of joint									
ventures	-	-	-	-	3	-	3	-	3
Equity movements of									
associates	-	-	-	-	1	-	1	-	1
Income tax relating to items									
that may be reclassified	-	-	(776)	-	14	-	(762)	-	(762)
Other	-	(1)	-	-	-	-	(1)	7	6
<b>Total other comprehensive</b>									
<b>income</b>	-	(1)	1,337	(313)	(769)	-	255	7	261
<b>Total comprehensive</b>									
<b>income / (loss) for 2016</b>	-	143	1,337	(313)	(769)	-	398	7	405
Issuance and purchase of									
(treasury) shares	-	(200)	-	-	-	-	(200)	-	(200)
Coupons on non-cumulative									
subordinated notes	-	(7)	-	-	-	-	(7)	-	(7)
Coupons on perpetual									
securities	-	(28)	-	-	-	-	(28)	-	(28)
Incentive plans	-	-	-	-	-	11	11	-	11
<b>At end of period</b>	<b>8,387</b>	<b>7,984</b>	<b>7,808</b>	<b>(1,845)</b>	<b>513</b>	<b>3,811</b>	<b>26,659</b>	<b>16</b>	<b>26,674</b>

<sup>1</sup> For a breakdown of share capital please refer to note 16.

<sup>2</sup> Issued capital and reserves attributable to owners of Aegon N.V.

Unaudited

**Table of Contents****6 Condensed Consolidated Interim Financial Statements 1Q 2017****Condensed consolidated cash flow statement**

<i>EUR millions</i>	YTD 2017	YTD 2016
<b>Cash flow from operating activities</b>	<b>(2,097)</b>	<b>2,799</b>
Purchases and disposals of intangible assets	(1)	(8)
Purchases and disposals of equipment and other assets	(21)	(8)
Purchases and disposals of businesses and subsidiaries	(51)	-
Purchases, disposals and dividends joint ventures and associates	(27)	23
<b>Cash flow from investing activities</b>	<b>(100)</b>	<b>6</b>
Purchase of treasury shares	-	(200)
Issuances, repurchases and coupons of perpetuals	(36)	(37)
Issuances, repurchases and coupons of non-cumulative subordinated notes	(10)	(9)
Issuances and repayments of borrowings	1,957	(1,431)
<b>Cash flow from financing activities</b>	<b>1,911</b>	<b>(1,677)</b>
<b>Net increase / (decrease) in cash and cash equivalents</b>	<b>(286)</b>	<b>1,128</b>
Net cash and cash equivalents at January 1	11,347	9,593
Effects of changes in foreign exchange rates	(26)	(146)
<b>Net cash and cash equivalents at end of period</b>	<b>11,034</b>	<b>10,576</b>
Cash and cash equivalents	11,037	10,616
Cash and cash equivalents classified as Assets held for sale	-	-
Bank overdrafts classified as other liabilities	(3)	(40)
<b>Net cash and cash equivalents</b>	<b>11,034</b>	<b>10,576</b>

Unaudited

**Table of Contents**

## Condensed Consolidated Interim Financial Statements 1Q 2017

7

## Notes to the Condensed consolidated interim financial statements

## Amounts in EUR millions, unless otherwise stated

Aegon N.V., incorporated and domiciled in the Netherlands, is a public limited liability company organized under Dutch law and recorded in the Commercial Register of The Hague under number 27076669 and with its registered address at Aegonplein 50, 2591 TV, The Hague, the Netherlands. Aegon N.V. serves as the holding company for the Aegon Group and has listings of its common shares in Amsterdam and New York.

Aegon N.V. (or the Company) and its subsidiaries (Aegon or the Group) have life insurance and pensions operations in more than 20 countries in the Americas, Europe and Asia and are also active in savings and asset management operations, accident and health insurance, general insurance and to a limited extent banking operations. Headquarters are located in The Hague, the Netherlands. The Group employs over 29,000 people worldwide.

**1. Basis of presentation**

The condensed consolidated interim financial statements as at and for the period ended, March 31, 2017, have been prepared in accordance with IAS 34 Interim Financial Reporting, as adopted by the European Union (hereafter IFRS). They do not include all of the information required for a full set of financial statements prepared in accordance with IFRS and should therefore be read together with the 2016 consolidated financial statements of Aegon N.V. as included in Aegon's Annual Report for 2016. Aegon's Annual Report for 2016 is available on its website (aegon.com).

The condensed consolidated interim financial statements have been prepared in accordance with the historical cost convention as modified by the revaluation of investment properties and those financial instruments (including derivatives) and financial liabilities that have been measured at fair value. Certain amounts in prior periods may have been reclassified to conform to the current year presentation. These reclassifications had no effect on net income, shareholders' equity or earnings per share. The condensed consolidated interim financial statements as at, and for the period ended March 31, 2017, were approved by the Executive Board on May 10, 2017.

The condensed consolidated interim financial statements are presented in euro (EUR) and all values are rounded to the nearest million unless otherwise stated. The consequence is that the rounded amounts may not add up to the rounded total in all cases.

The published figures in these condensed consolidated interim financial statements are unaudited.

Unaudited

**Table of Contents**

**8 Condensed Consolidated Interim Financial Statements 1Q 2017**

**2. Significant accounting policies**

All accounting policies and methods of computation applied in the condensed consolidated interim financial statements are the same as those applied in the 2016 consolidated financial statements.

*New IFRS accounting standards effective*

The following standards, interpretations, amendments to standards and interpretations became effective in 2017, but have not yet been endorsed by the European Union:

- t IAS 7 Amendment Disclosure initiative;
- t IAS 12 Recognition of Deferred Tax Assets for Unrealised Losses; and
- t Annual improvements 2014-2016 Cycle.

None of these revised standards and interpretations will significantly impact the financial position or the condensed consolidated interim financial statements.

For a complete overview of IFRS standards, published before January 1, 2017, that will be applied in future years, and were not early adopted by the Group, please refer to Aegon's Annual Report for 2016.

*Taxes*

Taxes on income for the three month period, ended March 31, 2017, are calculated using the tax rate that is estimated to be applicable to total annual earnings.

*Judgments and critical accounting estimates*

Preparing the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions, including the likelihood, timing or amount of future transactions or events, that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from the estimates made.

In preparing the condensed consolidated interim financial statements, significant judgments made by management in applying the Group's accounting policies and the key sources of estimating uncertainty were not significantly different than those that were applied to the consolidated financial statements as at and for the year ended December 31, 2016.

*Exchange rates*

Assets and liabilities are translated at the closing rates on the reporting date. Income, expenses and capital transactions (such as dividends) are translated at average exchange rates or at the prevailing rates on the transaction date, if more

appropriate. The following exchange rates are applied for the condensed consolidated interim financial statements:

Closing exchange rates

			USD	GBP
March 31, 2017	1	EUR	1.0696	0.8553
December 31, 2016	1	EUR	1.0548	0.8536
Weighted average exchange rates				

			USD	GBP
Three months ended				
March 31, 2017	1	EUR	1.0647	0.8594
Three months ended				
March 31, 2016	1	EUR	1.1023	0.7698

Unaudited

**Table of Contents**

Condensed Consolidated Interim Financial Statements 1Q 2017

9

**3. Segment information****3.1 Income statement**

	The Americas		United Kingdom	Central & Eastern Europe	Spain & Portugal	Europe	Management	Asset	other	Eliminations	Segment eliminations	Joint ventures and associates	Consolidated
<i>EUR million</i>													
<b>Three months ended March 31, 2017</b>													
<b>Underlying earnings before tax</b>	<b>313</b>	<b>118</b>	<b>33</b>	<b>17</b>	<b>1</b>	<b>169</b>	<b>12</b>	<b>37</b>	<b>(44)</b>	<b>1</b>	<b>488</b>	<b>9</b>	<b>496</b>
Fair value items	(20)	(35)	(21)	-	-	(56)	1	-	22	-	(53)	(22)	(75)
Realized gains / (losses) on investments	10	62	3	1	-	67	(3)	2	-	-	76	(1)	75
Impairment charges	(6)	(7)	-	(1)	-	(7)	-	-	(2)	-	(16)	-	(16)
Impairment reversals	2	3	-	-	-	3	-	-	-	-	4	-	4
Other income / (charges)	(2)	-	8	-	-	8	-	-	-	-	6	-	6
Run-off businesses	31	-	-	-	-	-	-	-	-	-	31	-	31
<b>Income / (loss) before tax</b>	<b>328</b>	<b>141</b>	<b>24</b>	<b>18</b>	<b>1</b>	<b>183</b>	<b>10</b>	<b>39</b>	<b>(24)</b>	<b>1</b>	<b>536</b>	<b>(14)</b>	<b>523</b>
Income tax (expense) /	(86)	(30)	(18)	(3)	(2)	(53)	(14)	(12)	6	-	(159)	14	(145)



benefit													
<b>Net income / (loss)</b>	<b>242</b>	<b>111</b>	<b>6</b>	<b>15</b>	<b>(1)</b>	<b>131</b>	<b>(4)</b>	<b>27</b>	<b>(18)</b>	<b>1</b>	<b>378</b>	<b>-</b>	<b>378</b>
<i>Inter-segment underlying earnings</i>	<i>(19)</i>	<i>(30)</i>	<i>(22)</i>	<i>(3)</i>	<i>-</i>	<i>(56)</i>	<i>(1)</i>	<i>57</i>	<i>19</i>				
<b>Revenues</b>													
Life insurance gross premiums	1,965	693	1,887	103	54	2,737	325	-	2	(2)	5,026	(195)	4,832
Accident and health insurance	564	110	8	-	81	200	33	-	-	-	796	(13)	783
General insurance	-	40	-	55	24	118	-	-	1	(1)	118	(24)	94
<b>Total gross premiums</b>	<b>2,529</b>	<b>843</b>	<b>1,895</b>	<b>157</b>	<b>160</b>	<b>3,055</b>	<b>358</b>	<b>-</b>	<b>2</b>	<b>(3)</b>	<b>5,941</b>	<b>(231)</b>	<b>5,710</b>
Investment income	972	548	272	11	9	840	65	1	79	(77)	1,880	(17)	1,863
Fee and commission income	396	87	61	10	4	161	16	153	-	(60)	666	(45)	621
Other revenues	1	-	-	-	1	-	-	-	1	-	3	(1)	1
<b>Total revenues</b>	<b>3,898</b>	<b>1,477</b>	<b>2,228</b>	<b>178</b>	<b>173</b>	<b>4,057</b>	<b>440</b>	<b>154</b>	<b>82</b>	<b>(140)</b>	<b>8,490</b>	<b>(294)</b>	<b>8,196</b>
<i>Inter-segment revenues</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>1</i>	<i>60</i>	<i>80</i>				

											Joint		
	The Americas		Central & Eastern Europe		Spain & Portugal		Holding and Asset Management		other activities		ventures and Segment eliminations		Consolidated
<i>EUR million</i>	<i>Americas</i>	<i>Netherlands</i>	<i>Kingdom</i>	<i>Europe</i>	<i>Portugal</i>	<i>Europe</i>	<i>Management</i>	<i>activities</i>	<i>eliminations</i>	<i>eliminations</i>	<i>eliminations</i>	<i>eliminations</i>	<i>Consolidated</i>
<b>Three months ended March 31, 2016</b>													
<b>Underlying earnings before tax</b>	<b>283</b>	<b>128</b>	<b>23</b>	<b>15</b>	<b>3</b>	<b>169</b>	<b>-</b>	<b>45</b>	<b>(37)</b>	<b>1</b>	<b>462</b>	<b>6</b>	<b>468</b>
Fair value items	(220)	(105)	34	-	-	(71)	3	-	(70)	-	(358)	(13)	(370)
	33	18	1	-	(1)	17	4	-	-	-	54	(1)	53

Realized gains / (losses) on investments													
Impairment charges	(34)	(5)	-	2	-	(3)	(1)	-	(4)	-	(42)	-	(42)
Impairment reversals	2	4	-	-	-	4	-	-	-	-	6	-	6
Other income / (charges)	(6)	-	1	-	-	1	-	-	-	-	(6)	-	(6)
Run-off businesses	28	-	-	-	-	-	-	-	-	-	28	-	28
<b>Income / (loss) before tax</b>	<b>87</b>	<b>40</b>	<b>58</b>	<b>16</b>	<b>2</b>	<b>116</b>	<b>6</b>	<b>45</b>	<b>(110)</b>	<b>1</b>	<b>145</b>	<b>(7)</b>	<b>138</b>
Income tax (expense) / benefit	7	(7)	(6)	(2)	(2)	(17)	(5)	(13)	26	-	(1)	7	6
<b>Net income / (loss)</b>	<b>94</b>	<b>33</b>	<b>52</b>	<b>14</b>	<b>-</b>	<b>99</b>	<b>1</b>	<b>32</b>	<b>(84)</b>	<b>1</b>	<b>143</b>	<b>-</b>	<b>143</b>
<i>Inter-segment underlying earnings</i>	<i>(55)</i>	<i>(12)</i>	<i>(13)</i>	<i>(3)</i>	<i>-</i>	<i>(28)</i>	<i>21</i>	<i>65</i>	<i>(3)</i>				

**Revenues**

Life insurance gross premiums	1,770	858	2,015	98	49	3,020	299	-	1	(21)	5,069	(170)	4,899
Accident and health insurance	548	121	11	-	72	204	33	-	4	(1)	787	(11)	775
General insurance	-	115	-	47	23	184	-	-	-	-	184	(23)	161
<b>Total gross premiums</b>	<b>2,318</b>	<b>1,094</b>	<b>2,026</b>	<b>145</b>	<b>144</b>	<b>3,408</b>	<b>331</b>	<b>-</b>	<b>5</b>	<b>(22)</b>	<b>6,040</b>	<b>(204)</b>	<b>5,836</b>
Investment income	916	522	431	11	10	974	57	1	81	(81)	1,948	(13)	1,935
Fee and commission income	418	86	23	9	3	121	14	167	-	(64)	656	(54)	602
Other revenues	1	-	-	-	1	1	-	-	1	-	2	(1)	1
<b>Total revenues</b>	<b>3,652</b>	<b>1,702</b>	<b>2,480</b>	<b>164</b>	<b>157</b>	<b>4,504</b>	<b>403</b>	<b>168</b>	<b>87</b>	<b>(167)</b>	<b>8,646</b>	<b>(272)</b>	<b>8,374</b>
<i>Inter-segment revenues</i>	<i>-</i>	<i>1</i>	<i>-</i>	<i>-</i>	<i>-</i>	<i>1</i>	<i>20</i>	<i>64</i>	<i>82</i>				

**3.2 Performance measure**

Aegon's segment information is prepared by consolidating on a proportionate basis Aegon's joint ventures and associated companies.

*Performance measure*

A performance measure of reporting segments utilized by the Company is underlying earnings before tax. Underlying earnings before tax reflects Aegon's profit from underlying business operations and excludes components that relate to accounting mismatches that are dependent on market volatility, updates to best estimate actuarial and economic assumptions and model updates or events that are considered outside the normal course of business. Note that, as disclosed in the 2016 Annual Report, Aegon changed the measurement of underlying earnings before tax to exclude the impact of actuarial assumption updates. In addition, updates to economic assumptions previously recorded in fair value items, are recorded in Other income / (charges). These changes had no effect on 1Q 2016 numbers.

Aegon believes that its performance measure, underlying earnings before tax, provides meaningful information about the underlying results of Aegon's business, including insight into the financial measures that Aegon's senior management uses in managing the business. Among other things, Aegon's senior management is compensated based in part on Aegon's results against targets using underlying earnings before tax. While many other insurers in Aegon's peer group present substantially similar performance measures, the performance measures presented in this document may nevertheless differ from the performance measures presented by other insurers. There is no standardized meaning to these measures under IFRS or any other recognized set of accounting standards.

Unaudited

**Table of Contents**

10	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

The reconciliation from underlying earnings before tax to income before tax, being the most comparable IFRS measure, is presented in the tables in this note.

The items that are excluded from underlying earnings before tax as described further below are: fair value items, realized gain or losses on investments, impairment charges/reversals, other income or charges, run-off businesses and share in earnings of joint ventures and associates.

*Fair value items*

Fair value items include the over- or underperformance of investments and guarantees held at fair value for which the expected long-term return is included in underlying earnings before tax.

In addition, hedge ineffectiveness on hedge transactions, fair value changes on economic hedges without natural offset in earnings and for which no hedge accounting is applied and fair value movements on real estate are included under fair value items.

Certain assets held by Aegon are carried at fair value and managed on a total return basis, with no offsetting changes in the valuation of related liabilities. These include assets such as investments in hedge funds, private equities, real estate (limited partnerships), convertible bonds and structured products. Underlying earnings before tax exclude any over- or underperformance compared to management's long-term expected return on assets. Based on current holdings and asset returns, the long-term expected return on an annual basis is 8-10%, depending on asset class, including cash income and market value changes. The expected earnings from these asset classes are net of deferred policy acquisition costs (DPAC) where applicable.

In addition, certain products offered by Aegon Americas contain guarantees and are reported on a fair value basis and the total return annuities and guarantees on variable annuities. The earnings on these products are impacted by movements in equity markets and risk-free interest rates. Short-term developments in the financial markets may therefore cause volatility in earnings. Included in underlying earnings before tax is a long-term expected return on these products and excluded is any over- or underperformance compared to management's expected return.

The fair value movements of certain guarantees and the fair value change of derivatives that hedge certain risks on these guarantees of Aegon the Netherlands, VA Europe (included in United Kingdom) and Japan are excluded from underlying earnings before tax, and the long-term expected return for these guarantees is set at zero. In addition, fair value items include market related results on our loyalty bonus reserves in the United Kingdom. The value of these reserves are directly related to policyholder investments which value is directly impacted by movements in equity and bond markets.

Holding and other activities include certain issued bonds that are held at fair value through profit or loss (FVTPL). The interest rate risk on these bonds is hedged using swaps. The fair value movement resulting from changes in Aegon's credit spread used in the valuation of these bonds are excluded from underlying earnings before tax and reported under fair value items.

*Realized gains or losses on investments*

Includes realized gains and losses on available-for-sale investments, mortgage loans and other loan portfolios.

*Impairment charges/reversals*

Impairment charges include impairments on available-for-sale debt securities, shares including the effect of deferred policyholder acquisition costs, mortgage loans and other loan portfolios at amortized cost, joint ventures and associates. Impairment reversals include reversals on available-for-sale debt securities.

Unaudited

**Table of Contents**

Condensed Consolidated Interim Financial Statements 1Q 2017

11

*Other income or charges*

Other income or charges includes: a) items which cannot be directly allocated to a specific line of business; b) the impact of assumption and model updates used to support calculations of our liabilities for insurance and investment contracts sold to policyholders and related assets; and c) items that are outside the normal course of business, including restructuring charges. In the condensed consolidated interim financial statements, these restructuring charges are included in operating expenses. Actuarial assumption and model updates are recorded in Claims and Benefits in the IFRS income statement.

*Run-off businesses*

Includes underlying results of business units where management has decided to exit the market and to run-off the existing block of business. Currently, this line includes results related to the run-off of the institutional spread-based business, structured settlements blocks of business, bank-owned and corporate-owned life insurance (BOLI/COLI) business, and the sale of the life reinsurance business in the United States. Aegon has other blocks of business for which sales have been discontinued and of which the earnings are included in underlying earnings before tax.

*Share in earnings of joint ventures and associates*

Earnings from Aegon's joint ventures in the Netherlands, Mexico, Spain, Portugal, China and Japan and Aegon's associates in India, Brazil, the Netherlands, United Kingdom, Mexico and France are reported on an underlying earnings before tax basis.

Unaudited

**Table of Contents**

12

Condensed Consolidated Interim Financial Statements 1Q 2017

**3.2 Investments**

Amounts included in the tables on investments are presented on an IFRS basis.

EUR millions										
March 31, 2017	Holdings						Asset and other		Eliminations	Total
	Americas	The Netherlands	United Kingdom	Central & Eastern Europe	Spain & Portugal	Europe	Asset Management activities	and other		
Investments										EUR
Shares	783	623	104	40	5	772	-	2	58	1,616
Debt securities	69,953	22,639	2,060	665	665	26,030	5,293	-	-	101,276
Loans	10,513	28,968	-	308	49	29,324	6	-	-	39,843
Other financial assets	10,555	321	115	7	-	443	-	77	22	11,097
Investments in real estate	727	1,269	-	3	15	1,287	-	-	-	2,014
<b>Investments general account</b>	<b>92,531</b>	<b>53,820</b>	<b>2,279</b>	<b>1,024</b>	<b>734</b>	<b>57,857</b>	<b>5,299</b>	<b>79</b>	<b>81</b>	<b>- 155,847</b>
Shares	-	9,534	15,878	291	14	25,718	-	-	-	(6) 25,712
Debt securities	4,635	14,993	10,336	218	9	25,555	-	-	-	- 30,190
Unconsolidated investment funds	104,726	-	37,631	908	67	38,606	-	-	-	- 143,332
Other financial assets	56	2,795	3,519	9	1	6,323	-	-	-	- 6,379
Investments in real estate	-	-	681	-	-	681	-	-	-	- 681
<b>Investments for account of policyholders</b>	<b>109,417</b>	<b>27,321</b>	<b>68,044</b>	<b>1,427</b>	<b>90</b>	<b>96,883</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(6) 206,294</b>
<b>Investments on balance sheet</b>	<b>201,947</b>	<b>81,142</b>	<b>70,324</b>	<b>2,451</b>	<b>824</b>	<b>154,740</b>	<b>5,299</b>	<b>79</b>	<b>81</b>	<b>(6) 362,141</b>
<b>Off balance sheet investments</b>										
<b>third parties</b>	<b>244,916</b>	<b>977</b>	<b>107,686</b>	<b>3,376</b>	<b>528</b>	<b>112,568</b>	<b>2,852</b>	<b>125,821</b>	<b>-</b>	<b>(1,063) 485,094</b>
	<b>446,863</b>	<b>82,119</b>	<b>178,010</b>	<b>5,827</b>	<b>1,352</b>	<b>267,308</b>	<b>8,151</b>	<b>125,900</b>	<b>81</b>	<b>(1,069) 847,234</b>

**Total revenue  
generating  
investments**

**Investments**

Available-for-sale	77,728	22,089	2,176	697	670	25,632	5,271	75	22	-	108,727
Loans	10,513	28,968	-	308	49	29,324	6	-	-	-	39,843
Financial assets at fair value through profit or loss	112,979	28,816	67,467	1,442	90	97,816	23	4	58	(6)	210,875
Investments in real estate	727	1,269	681	3	15	1,968	-	-	-	-	2,695
<b>Total investments on balance sheet</b>	<b>201,947</b>	<b>81,142</b>	<b>70,324</b>	<b>2,451</b>	<b>824</b>	<b>154,740</b>	<b>5,299</b>	<b>79</b>	<b>81</b>	<b>(6)</b>	<b>362,141</b>
Investments in joint ventures	7	895	-	-	499	1,394	140	108	-	-	1,648
Investments in associates	99	33	8	2	-	42	21	127	(1)	-	288
Other assets	28,976	15,289	12,981	292	231	28,779	2,812	323	31,395	(30,921)	61,378
<b>Consolidated total assets</b>	<b>231,029</b>	<b>97,358</b>	<b>83,313</b>	<b>2,744</b>	<b>1,554</b>	<b>184,955</b>	<b>8,272</b>	<b>637</b>	<b>31,475</b>	<b>(30,927)</b>	<b>425,455</b>

EUR millions

December 31, 2016	Holdings										Total EUR
	Central & The United EasternSpain & AmericasNetherlandsKingdom EuropePortugal					Assetand other Management activitiesEliminations					
	Americas	Netherlands	Kingdom	Europe	Portugal	Europe	AS	Management activities	Eliminations		
Investments											
Shares	793	334	84	35	4	457	-	2	62	-	1,314
Debt securities	70,766	23,741	2,036	633	683	27,093	5,310	-	-	-	103,169
Loans	10,820	28,627	-	303	45	28,975	18	-	-	-	39,812
Other financial assets	9,924	358	115	10	-	483	-	88	23	-	10,519
Investments in real estate	743	1,238	-	3	15	1,256	-	-	-	-	1,999
Investments general account	93,046	54,298	2,236	983	747	58,264	5,328	90	85	-	156,813
Shares	-	9,689	15,503	295	13	25,499	-	-	-	(7)	25,492
Debt securities	4,779	15,434	9,847	235	10	25,526	-	-	-	-	30,305
Unconsolidated investment funds	102,534	-	36,600	879	64	37,543	-	-	-	-	140,077
Other financial assets	27	2,862	4,150	9	1	7,022	-	-	-	-	7,049
Investments in real estate	-	-	686	-	-	686	-	-	-	-	686
Investments for account of policyholders	107,341	27,985	66,786	1,418	88	96,276	-	-	-	(7)	203,610



<b>Investments on balance sheet</b>	<b>200,387</b>	<b>82,283</b>	<b>69,021</b>	<b>2,401</b>	<b>834</b>	<b>154,540</b>	<b>5,328</b>	<b>90</b>	<b>85</b>	<b>(7)</b>	<b>360,423</b>
<b>Off balance sheet investments</b>											
<b>third parties</b>	<b>240,072</b>	<b>952</b>	<b>5,333</b>	<b>3,154</b>	<b>507</b>	<b>9,946</b>	<b>2,734</b>	<b>130,889</b>	<b>-</b>	<b>(864)</b>	<b>382,776</b>
<b>Total revenue generating investments</b>	<b>440,458</b>	<b>83,235</b>	<b>74,354</b>	<b>5,556</b>	<b>1,342</b>	<b>164,487</b>	<b>8,061</b>	<b>130,979</b>	<b>85</b>	<b>(871)</b>	<b>743,200</b>
<b>Investments</b>											
Available-for-sale	77,918	23,044	2,152	660	687	26,544	5,289	87	23	-	109,860
Loans	10,820	28,627	-	303	45	28,975	18	-	-	-	39,812
Financial assets at fair value through profit or loss	110,906	29,374	66,183	1,436	88	97,080	21	4	62	(7)	208,066
Investments in real estate	743	1,238	686	3	15	1,942	-	-	-	-	2,685
<b>Total investments on balance sheet</b>	<b>200,387</b>	<b>82,283</b>	<b>69,021</b>	<b>2,401</b>	<b>834</b>	<b>154,540</b>	<b>5,328</b>	<b>90</b>	<b>85</b>	<b>(7)</b>	<b>360,423</b>
Investments in joint ventures	7	877	-	-	495	1,373	134	99	-	-	1,614
Investments in associates	95	21	8	2	-	30	21	125	(1)	-	270
Other assets	31,003	15,260	12,718	293	170	28,426	3,122	293	31,107	(30,338)	63,627
<b>Consolidated total assets</b>	<b>231,493</b>	<b>98,441</b>	<b>81,747</b>	<b>2,696</b>	<b>1,500</b>	<b>184,370</b>	<b>8,604</b>	<b>607</b>	<b>31,192</b>	<b>(30,345)</b>	<b>425,935</b>

Unaudited

**Table of Contents**

Condensed Consolidated Interim Financial Statements 1Q 2017

13

**4. Premium income and premiums paid to reinsurers**

<i>EUR millions</i>	1Q 2017	1Q 2016
<b>Premium income</b>		
Life insurance	4,832	4,899
Non-life insurance	878	937
<b>Total premium income</b>	<b>5,710</b>	<b>5,836</b>
Accident and health insurance	783	775
General insurance	94	161
<b>Non-life Insurance premium income</b>	<b>878</b>	<b>937</b>
<b>Premiums paid to reinsurers 1</b>		
Life insurance	751	646
Non-life insurance	61	67
<b>Total premiums paid to reinsurers</b>	<b>812</b>	<b>713</b>
Accident and health insurance	58	63
General insurance	3	4
<b>Non-life Insurance paid to reinsurers</b>	<b>61</b>	<b>67</b>

1 Premiums paid to reinsurers are recorded within Benefits and expenses in the income statement - refer to note 8 - Benefits and expenses.

Premium income Life includes EUR 771 million for 1Q 2017 (1Q 2016: EUR 802 million) of premiums related to insurance policies upgraded to the retirement platform in the UK.

**5. Investment income**

<i>EUR millions</i>	1Q 2017	1Q 2016
Interest income	1,636	1,707
Dividend income	192	194
Rental income	35	34
<b>Total investment income</b>	<b>1,863</b>	<b>1,935</b>
Investment income related to general account	1,464	1,493

Investment income for account of policyholders	399	442
<b>Total</b>	<b>1,863</b>	<b>1,935</b>

Unaudited

**Table of Contents**

14	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

**6. Results from financial transactions**

EUR millions	1Q 2017	1Q 2016
Net fair value change of general account financial investments at FVTPL other than derivatives	25	(72)
Realized gains /(losses) on financial investments	78	53
Gains /(losses) on investments in real estate	24	18
Net fair value change of derivatives	(444)	438
Net fair value change on for account of policyholder financial assets at FVTPL	6,997	1,596
Net fair value change on investments in real estate for account of policyholders	7	8
Net foreign currency gains /(losses)	2	17
Net fair value change on borrowings and other financial liabilities	5	(9)
<b>Total</b>	<b>6,694</b>	<b>2,050</b>

The increase of the net fair value change on for account of policyholder financial assets at FVTPL in 1Q 2017 compared to 1Q 2016 is mainly driven by the equity markets and interest rate movements.

Net fair value change on for accounts of policyholder financial assets at FVTPL is offset by amounts in the Claims and benefits line reported in note 8 - Benefits and expenses.

**7. Other income**

Other income of EUR 9 million reflects an extension of the existing reinsurance arrangement with Rothesay Life as amended and supplemented in 2017, covering the new business written from January 1 to September 5, 2016.

**8. Benefits and expenses**

EUR millions	1Q 2017	1Q 2016
Claims and benefits	14,183	10,041
Employee expenses	590	596
Administration expenses	339	311
Deferred expenses	(262)	(323)
Amortization charges	204	277
<b>Total</b>	<b>15,055</b>	<b>10,901</b>

Unaudited

**Table of Contents**

## Condensed Consolidated Interim Financial Statements 1Q 2017

15

The following table provides an analysis of claims and benefits :

<i>EUR millions</i>	1Q 2017	1Q 2016
Benefits and claims paid life	6,230	4,711
Benefits and claims paid non-life	504	538
Change in valuation of liabilities for insurance contracts	5,479	3,000
Change in valuation of liabilities for investment contracts	460	284
Other	(10)	(5)
<b>Policyholder claims and benefits</b>	<b>12,664</b>	<b>8,527</b>
Premium paid to reinsurers	812	713
Profit sharing and rebates	6	7
Commissions	701	795
<b>Total</b>	<b>14,183</b>	<b>10,041</b>
<p>The lines change in valuation of liabilities for insurance contracts and change in valuation of liabilities for investment contracts reflect changes in technical provisions resulting from net fair value changes on for account of policyholder financial assets at fair value through P&amp;L included in Results from financial transactions (note 6) of EUR 6,997 million (1Q 2016: EUR 1,596 million). In addition, the line change in valuation of liabilities for insurance contracts includes a decrease of technical provisions for life insurance contracts of EUR 194 million (1Q 2016: increase of EUR 1,863 million).</p>		

**9. Impairment charges/(reversals)**

<i>EUR millions</i>	1Q 2017	1Q 2016
<b>Impairment charges / (reversals) comprise:</b>		
Impairment charges on financial assets, excluding receivables	17	45
Impairment reversals on financial assets, excluding receivables	(4)	(6)
Impairment charges / (reversals) on non-financial assets and receivables	-	1
<b>Total</b>	<b>13</b>	<b>40</b>
<b>Impairment charges on financial assets, excluding receivables, from:</b>		
Shares	-	1
Debt securities and money market instruments	6	28

Loans	8	3
Other	-	9
Investments in associates	2	4
<b>Total</b>	<b>17</b>	<b>45</b>

**Impairment reversals on financial assets, excluding receivables, from:**

Debt securities and money market instruments	(1)	(1)
Loans	(3)	(4)
Other	(1)	-
<b>Total</b>	<b>(4)</b>	<b>(6)</b>

Unaudited

**Table of Contents**

16	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

**10. Investments**

<i>EUR millions</i>	Mar. 31, 2017	Dec. 31, 2016
Available-for-sale (AFS)	108,727	109,860
Loans	39,843	39,812
Financial assets at fair value through profit or loss (FVTPL)	5,261	5,142
<b>Financial assets, for general account, excluding derivatives</b>	<b>153,832</b>	<b>154,814</b>
Investments in real estate	2,014	1,999
<b>Total investments for general account, excluding derivatives</b>	<b>155,847</b>	<b>156,813</b>

**Financial assets, for general account, excluding derivatives**

<i>EUR millions</i>	AFS	FVTPL	Loans	Total
Shares	1,038	578	-	1,616
Debt securities	99,150	2,126	-	101,276
Money market and other short-term investments	7,369	334	-	7,703
Mortgages loans	-	-	34,211	34,211
Private loans	-	-	3,230	3,230
Deposits with financial institutions	-	-	141	141
Policy loans	-	-	2,162	2,162
Other	1,171	2,224	100	3,494
<b>March 31, 2017</b>	<b>108,727</b>	<b>5,261</b>	<b>39,843</b>	<b>153,832</b>
	AFS	FVTPL	Loans	Total
Shares	824	490	-	1,314
Debt securities	101,054	2,115	-	103,169
Money market and other short-term investments	6,776	317	-	7,093
Mortgages loans	-	-	34,206	34,206
Private loans	-	-	3,166	3,166
Deposits with financial institutions	-	-	129	129
Policy loans	-	-	2,207	2,207



Other	1,206	2,219	104	3,529
<b>December 31, 2016</b>	<b>109,860</b>	<b>5,142</b>	<b>39,812</b>	<b>154,814</b>

### 11. Investments for account of policyholders

<i>EUR millions</i>	Mar. 31, 2017	Dec. 31, 2016
Shares	25,712	25,492
Debt securities	30,190	30,305
Money market and short-term investments	1,191	1,231
Deposits with financial institutions	2,353	2,951
Unconsolidated investment funds	143,332	140,077
Other	2,835	2,868
<b>Total investments for account of policyholders at fair value through profit or loss, excluding derivatives</b>	<b>205,613</b>	<b>202,924</b>
Investment in real estate	681	686
<b>Total investments for account of policyholders</b>	<b>206,294</b>	<b>203,610</b>

### 12. Derivatives

The movements in fair value of derivatives on both the asset and liability side of the condensed consolidated statement of financial position mainly result from changes in interest rates and other market movements during the period, as well as purchases and disposals.

Unaudited

Table of Contents

## Condensed Consolidated Interim Financial Statements 1Q 2017

17

**13. Fair value**

The following tables provide an analysis of financial instruments recorded at fair value on a recurring basis by level of the fair value hierarchy:

**Fair value hierarchy**

<i>EUR millions</i>	Level I	Level II	Level III	Total
<b>As at March 31, 2017</b>				
<b>Financial assets carried at fair value</b>				
<b>Available-for-sale investments</b>				
Shares	149	321	567	1,038
Debt securities	28,238	69,035	1,877	99,150
Money markets and other short-term instruments	-	7,369	-	7,369
Other investments at fair value	-	414	757	1,171
<b>Total Available-for-sale investments</b>	<b>28,388</b>	<b>77,139</b>	<b>3,200</b>	<b>108,727</b>
<b>Fair value through profit or loss</b>				
Shares	295	164	119	578
Debt securities	13	2,107	5	2,126
Money markets and other short-term instruments	-	334	-	334
Other investments at fair value	1	1,003	1,219	2,224
Investments for account of policyholders <sup>1</sup>	127,837	76,048	1,728	205,613
Derivatives	23	7,526	127	7,676
<b>Total Fair value through profit or loss</b>	<b>128,169</b>	<b>87,182</b>	<b>3,199</b>	<b>218,551</b>
<b>Total financial assets at fair value</b>	<b>156,557</b>	<b>164,322</b>	<b>6,399</b>	<b>327,278</b>
<b>Financial liabilities carried at fair value</b>				
Investment contracts for account of policyholders <sup>2</sup>	-	42,884	195	43,079
Borrowings <sup>3</sup>	-	598	-	598
Derivatives	23	6,172	1,792	7,987
<b>Total financial liabilities at fair value</b>	<b>23</b>	<b>49,654</b>	<b>1,987</b>	<b>51,664</b>

## Fair value hierarchy

<i>EUR millions</i>	Level I	Level II	Level III	Total
<b>As at December 31, 2016</b>				
<b>Financial assets carried at fair value</b>				
<b>Available-for-sale investments</b>				
Shares	119	312	393	824
Debt securities	29,386	69,702	1,966	101,054
Money markets and other short-term instruments	-	6,776	-	6,776
Other investments at fair value	-	453	754	1,206
<b>Total Available-for-sale investments</b>	<b>29,504</b>	<b>77,243</b>	<b>3,112</b>	<b>109,860</b>
<b>Fair value through profit or loss</b>				
Shares	288	152	50	490
Debt securities	27	2,082	6	2,115
Money markets and other short-term instruments	-	317	-	317
Other investments at fair value	1	961	1,257	2,219
Investments for account of policyholders <sup>1</sup>	125,997	75,202	1,726	202,924
Derivatives	41	8,169	108	8,318
<b>Total Fair value through profit or loss</b>	<b>126,355</b>	<b>86,883</b>	<b>3,146</b>	<b>216,384</b>
<b>Total financial assets at fair value</b>	<b>155,860</b>	<b>164,126</b>	<b>6,259</b>	<b>326,244</b>
<b>Financial liabilities carried at fair value</b>				
Investment contracts for account of policyholders <sup>2</sup>	-	42,627	176	42,803
Borrowings <sup>3</sup>	-	610	-	610
Derivatives	64	6,347	2,467	8,878
<b>Total financial liabilities at fair value</b>	<b>64</b>	<b>49,584</b>	<b>2,643</b>	<b>52,290</b>

<sup>1</sup> The investments for account of policyholders included in the table above represents only those investments carried at fair value through profit or loss.

<sup>2</sup> The investment contracts for account of policyholders included in the table above represents only those investment contracts carried at fair value.

<sup>3</sup> Total borrowings on the statement of financial position contain borrowings carried at amortized cost that are not included in the above schedule.

Unaudited

**Table of Contents**

18	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

**Significant transfers between Level I, Level II and Level III**

Aegon's policy is to record transfers of assets and liabilities between Level I, Level II and Level III at their fair values as of the beginning of each reporting period.

The table below shows transfers between Level I and II for financial assets and financial liabilities recorded at fair value on a recurring basis during the three month period ended March 31, 2017.

**Fair value transfers***EUR millions*

	1Q 2017		Full Year 2016	
	Transfers Level I to Level II	Transfers Level II to Level I	Transfers Level I to Level II	Transfers Level II to Level I
<b>Financial assets carried at fair value</b>				
<b>Available-for-sale investments</b>				
Debt securities	-	-	5	69
<b>Total</b>	-	-	<b>5</b>	<b>69</b>
<b>Fair value through profit or loss</b>				
Investments for account of policyholders	-	10	3	(1)
<b>Total</b>	-	<b>10</b>	<b>3</b>	<b>(1)</b>
<b>Total financial assets at fair value</b>	-	<b>10</b>	<b>8</b>	<b>68</b>

Transfers are identified based on transaction volume and frequency, which are indicative of an active market.

**Movements in Level III financial instruments measured at fair value**

The following table summarizes the change of all assets and liabilities measured at estimated fair value on a recurring basis using significant unobservable inputs (Level III), including realized and unrealized gains (losses) of all assets and liabilities and unrealized gains (losses) of all assets and liabilities still held at the end of the respective period.

**Roll forward of Level III financial instruments***EUR millions*

January 2017	Total gains (losses) in income statement <sup>1</sup>	Total gains (losses) in OCI <sup>2</sup>	Purchases	Settlements	Reclassification exchange differences	Transfers from Level I and Level II	Transfers to Level I and Level II	Total 2017	Unrealized gains and losses for
--------------	---	--	-----------	-------------	---------------------------------------	-------------------------------------	-----------------------------------	------------	---------------------------------

the  
period recorded  
in the  
P&L  
for  
instruments  
held  
at  
March 31,  
  
2017  
3

**Financial assets  
carried at fair value  
available-for-sale  
investments**

Shares	393	16	(16)	206	(14)	(15)	(4)	-	-	-	567	-
Debt securities	1,966	4	16	65	(1)	(75)	(23)	-	6	(80)	1,877	-
Other investments at fair value	754	(35)	3	51	(7)	(1)	(10)	-	1	-	757	-
	<b>3,112</b>	<b>(15)</b>	<b>4</b>	<b>323</b>	<b>(22)</b>	<b>(91)</b>	<b>(38)</b>	<b>-</b>	<b>7</b>	<b>(80)</b>	<b>3,200</b>	<b>-</b>

**Fair value through  
profit or loss**

Shares	50	(1)	-	69	-	-	-	-	-	-	119	(1)
Debt securities	6	-	-	-	-	-	-	-	-	-	5	-
Other investments at fair value	1,257	(7)	-	58	(56)	-	(17)	-	73	(88)	1,219	(8)
Investments for account of policyholders	1,726	(14)	-	160	(102)	-	(3)	-	-	(38)	1,728	9
Derivatives	108	66	-	-	(21)	-	-	(26)	-	-	127	66
	<b>3,146</b>	<b>44</b>	<b>-</b>	<b>286</b>	<b>(179)</b>	<b>-</b>	<b>(20)</b>	<b>(26)</b>	<b>73</b>	<b>(126)</b>	<b>3,199</b>	<b>66</b>

**Financial liabilities  
carried at fair value**

Investment contracts for account of policyholders	176	(7)	-	30	(3)	-	(1)	-	-	-	195	-
Derivatives	2,467	(1,017)	-	-	351	-	(9)	-	-	-	1,792	(845)
	<b>2,643</b>	<b>(1,023)</b>	<b>-</b>	<b>30</b>	<b>348</b>	<b>-</b>	<b>(11)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>1,987</b>	<b>(846)</b>

<i>EUR millions</i>	January 2016	Total gains and losses in OCI <sup>2</sup>	Purchases and sales	Settlements	Reclassifications exchange differences	Net transfers from Level I to Level II	Transfers from Level II to Level I	Transfers from Level I to Level II	December 2016	Total	Unrealized gains and losses for the period recorded

in the  
P&L  
for  
instruments  
held  
at  
December  
31,  
2016  
3

**Financial assets  
carried at fair value  
available-for-sale  
investments**

Shares	293	27	(7)	161	(92)	(1)	11	-	-	-	393	-
Debt securities	4,144	1	92	443	(262)	(287)	39	-	651	(2,854)	1,966	-
Other investments at fair value	928	(177)	20	240	(133)	(141)	18	-	-	(1)	754	-
	<b>5,365</b>	<b>(150)</b>	<b>105</b>	<b>845</b>	<b>(487)</b>	<b>(429)</b>	<b>68</b>	<b>-</b>	<b>651</b>	<b>(2,856)</b>	<b>3,112</b>	<b>-</b>

**Fair value through  
profit or loss**

Shares	-	3	-	48	-	-	-	-	-	-	50	3
Debt securities	6	(1)	-	-	-	-	-	-	-	-	6	-
Other investments at fair value	1,265	(44)	-	178	(277)	-	35	-	419	(321)	1,257	(42)
Investments for account of policyholders	1,745	22	-	469	(395)	-	(35)	-	8	(88)	1,726	23
Derivatives	222	(285)	-	75	108	-	(12)	-	-	-	108	(287)
	<b>3,239</b>	<b>(305)</b>	<b>-</b>	<b>770</b>	<b>(564)</b>	<b>-</b>	<b>(11)</b>	<b>-</b>	<b>427</b>	<b>(409)</b>	<b>3,146</b>	<b>(303)</b>

**Financial liabilities  
carried at fair value**

Investment contracts for account of policyholders	156	(14)	-	45	(12)	-	2	-	-	(2)	176	1
Derivatives	2,104	542	-	-	(207)	-	28	-	-	-	2,467	562
	<b>2,260</b>	<b>528</b>	<b>-</b>	<b>45</b>	<b>(219)</b>	<b>-</b>	<b>31</b>	<b>-</b>	<b>-</b>	<b>(2)</b>	<b>2,643</b>	<b>563</b>

<sup>1</sup> Includes impairments and movements related to fair value hedges. Gains and losses are recorded in the line item results from financial transactions of the income statement.

<sup>2</sup> Total gains and losses are recorded in line items Gains/ (losses) on revaluation of available-for-sale investments and (Gains)/ losses transferred to the income statement on disposal and impairment of available-for-sale investment of the statement of other comprehensive income.

<sup>3</sup> Total gains / (losses) for the period during which the financial instrument was in Level III.



**Table of Contents**

## Condensed Consolidated Interim Financial Statements 1Q 2017

19

During the first three months of 2017, Aegon transferred certain financial instruments from Level II to Level III of the fair value hierarchy. The reason for the change in level was that the market liquidity for these securities decreased, which led to a change in market observability of prices. Prior to transfer, the fair value for the Level II securities was determined using observable market transactions or corroborated broker quotes respectively for the same or similar instruments. The amount of assets and liabilities transferred to Level III was EUR 80 million (full year 2016: EUR 1,077 million). Since the transfer, all such assets have been valued using valuation models incorporating significant non market-observable inputs or uncorroborated broker quotes.

Similarly, during the first three months of 2017, Aegon transferred EUR 206 million (full year 2016: EUR 3,266 million) of financial instruments from Level III to other levels of the fair value hierarchy. The change in level was mainly the result of a return of activity in the market for these securities and that for these securities the fair value could be determined using observable market transactions or corroborated broker quotes for the same or similar instruments.

The following table presents information about the significant unobservable inputs used for recurring fair value measurements for certain Level III financial instruments.

**Overview of significant unobservable inputs**

<i>EUR millions</i>	Carrying amount March 31, 2017	Valuation technique <sup>1</sup>	Significant unobservable input <sup>2</sup>	Range (weighted average)
<b>Financial assets carried at fair value available-for-sale investments</b>				
Shares	257	Net asset value <sup>4</sup>	n.a.	n.a.
	310	Other	n.a.	n.a.
	<b>567</b>			
Debt securities				
	1,334	Broker quote	n.a.	n.a.
	231	Discounted cash flow	Credit spread	1.28% -3.48% (2.86%)
	312	Other	n.a.	n.a.
	<b>1,877</b>			
Other investments at fair value				
Tax credit investments	678	Discounted cash flow	Discount rate	5.7%
Investment funds	45	Net asset value <sup>4</sup>	n.a.	n.a.



Other	33	Other	n.a.	n.a.
<b>March 31, 2017</b>	<b>757</b>			

**Fair value through profit or loss**

Shares	119	Other	n.a.	n.a.
Debt securities	5	Other	n.a.	n.a.
	<b>124</b>			

## Other investments at fair value

Investment funds	1,214	Net asset value <sup>4</sup>	n.a.	n.a.
Other	5	Other	n.a.	n.a.
	<b>1,219</b>			

## Derivatives

Longevity swap	5	Discounted cash flow	Mortality	n.a.
Longevity swap	46	Discounted cash flow	Risk free rate	0.40% -2.16% (2.05%)
Other	74	Other	n.a.	n.a.
<b>March 31, 2017</b>	<b>125</b>			

**Total financial assets at fair value <sup>3</sup>****4,668****Financial liabilities carried at fair value**

## Derivatives

Embedded derivatives in insurance contracts	1,766	Discounted cash flow	Own Credit spread	0.35% - 0.45% (0.37%)
Other	25	Other	n.a.	n.a.

**Total financial****liabilities at fair value****1,792**

<sup>1</sup> Other in the table above (column Valuation technique) includes investments for which the fair value is uncorroborated and no broker quote is received.

<sup>2</sup> Not applicable (n.a.) has been included when no significant unobservable assumption has been identified.

<sup>3</sup> Investments for account of policyholders are excluded from the table above and from the disclosure regarding reasonably possible alternative assumptions. Policyholder assets, and their returns, belong to policyholders and do not impact Aegon's net income or equity. The effect on total assets is offset by the effect on total liabilities. Derivatives exclude derivatives for account of policyholders amounting to EUR 2 million.

<sup>4</sup> Net asset value is considered the best approximation to the fair value of these financial instruments.

Unaudited

**Table of Contents**

20	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

The description of Aegon's methods of determining fair value is included in the consolidated financial statements for 2016. For reference purposes, the valuation techniques included in the table above are described in more detail on the following pages.

*Shares*

When available, Aegon uses quoted market prices in active markets to determine the fair value of its investments in shares. Fair values for unquoted shares are estimated using observations of the price/earnings or price/cash flow ratios of quoted companies considered comparable to the companies being valued. Valuations are adjusted to account for company-specific issues and the lack of liquidity inherent in an unquoted investment. Adjustments for illiquidity are generally based on available market evidence. In addition, a variety of other factors are reviewed by management, including, but not limited to, current operating performance, changes in market outlook and the third-party financing environment.

Available-for-sale shares include shares in a Federal Home Loan Bank (FHLB) for an amount of EUR 233 million (December 31, 2016: EUR 237 million) that are measured at par, which are reported as part of Other in the column Valuation technique. A FHLB has implicit financial support from the United States government. The redemption value of the shares is fixed at par and they can only be redeemed by the FHLB.

*Debt securities*

Aegon's portfolio of debt securities can be subdivided in Residential mortgage-backed securities (RMBS), Commercial mortgage-backed securities (CMBS), Asset-backed securities (ABS), Corporate bonds and Government debt. Below relevant details in the valuation methodology for these specific types of debt securities are described.

Valuations of RMBS, CMBS and ABS are monitored and reviewed on a monthly basis. Valuations per asset type are based on a pricing hierarchy which uses a waterfall approach that starts with market prices from indices and follows with third-party pricing services or brokers. The pricing hierarchy is dependent on the possibilities of corroboration of the market prices. If no market prices are available, Aegon uses internal models to determine fair value. Significant inputs included in the internal models are generally determined based on relative value analyses, which incorporate comparisons to instruments with similar collateral and risk profiles. Market standard models may be used to model the specific collateral composition and cash flow structure of each transaction.

Valuations of corporate bonds are monitored and reviewed on a monthly basis. The pricing hierarchy is dependent on the possibility of corroboration of market prices when available. If no market prices are available, valuations are determined by a discounted cash flow methodology using an internally calculated yield. The yield is comprised of a credit spread over a given benchmark. In all cases, the benchmark is an observable input. The credit spread contains both observable and unobservable inputs. Aegon starts by taking an observable credit spread from a similar bond of the given issuer, and then adjusts this spread based on unobservable inputs. These unobservable inputs may include subordination, liquidity and maturity differences. The weighted average credit spread used in valuation of corporate bonds has decreased to 2.9% (December 31, 2016: 3.1%).

If available, Aegon uses quoted market prices in active markets to determine the fair value of its Gouvernement debt investments. If Aegon cannot make use of quoted market prices, market prices from indices or quotes from third-party pricing services or brokers are used.

*Tax credit investments*

The fair value of tax credit investments is determined by using a discounted cash flow valuation technique. This valuation technique takes into consideration projections of future capital contributions and distributions, as well as future tax credits and the tax benefits of future operating losses. The present value of these cash flows is calculated by applying a discount rate. In general, the discount rate is determined based on the cash outflows for the investments and the cash inflows from the tax credits/tax benefits (and the timing of those cash flows). These inputs are unobservable in the market place. The discount rate used in valuation of tax credit investments has increased to 5.7% (December 31, 2016: 5.6%).

Unaudited

**Table of Contents**

Condensed Consolidated Interim Financial Statements 1Q 2017

21

*Investment funds*

Investment funds include real estate funds, private equity funds and hedge funds. The fair values of investments held in non-quoted investment funds are determined by management after taking into consideration information provided by the fund managers. Aegon reviews the valuations each month and performs analytical procedures and trending analyses to ensure the fair values are appropriate.

*Derivatives*

Where quoted market prices are not available, other valuation techniques, such as option pricing or stochastic modeling, are applied. The valuation techniques incorporate all factors that a typical market participant would consider and are based on observable market data when available. Models are validated before they are used and calibrated to ensure that outputs reflect actual experience and comparable market prices.

Fair values for exchange-traded derivatives, principally futures and certain options, are based on quoted market prices in active markets. Fair values for over-the-counter (OTC) derivatives represent amounts estimated to be received from or paid to a third party in settlement of these instruments. These derivatives are valued using pricing models based on the net present value of estimated future cash flows, directly observed prices from exchange-traded derivatives, other OTC trades, or external pricing services. Most valuations are derived from swap and volatility matrices, which are constructed for applicable indices and currencies using current market data from many industry standard sources. Option pricing is based on industry standard valuation models and current market levels, where applicable. The pricing of complex or illiquid instruments is based on internal models or an independent third party. For long-dated illiquid contracts, extrapolation methods are applied to observed market data in order to estimate inputs and assumptions that are not directly observable. To value OTC derivatives, management uses observed market information, other trades in the market and dealer prices.

Some OTC derivatives are so-called longevity derivatives. The payout of longevity derivatives is linked to publicly available mortality tables. The derivatives are measured using the present value of the best estimate of expected payouts of the derivative plus a risk margin. The best estimate of expected payouts is determined using best estimate of mortality developments. Aegon determined the risk margin by stressing the best estimate mortality developments to quantify the risk and applying a cost-of-capital methodology. The most significant unobservable input for these derivatives is the (projected) mortality development.

Aegon normally mitigates counterparty credit risk in derivative contracts by entering into collateral agreements where practical and in ISDA (International Swaps and Derivatives Association) master netting agreements for each of the Group's legal entities to facilitate Aegon's right to offset credit risk exposure. Changes in the fair value of derivatives attributable to changes in counterparty credit risk were not significant.

*Embedded derivatives in insurance contracts including guarantees*

All bifurcated guarantees for minimum benefits in insurance and investment contracts are carried at fair value. These guarantees include guaranteed minimum withdrawal benefits (GMWB) in the United States, United Kingdom and Japan which are offered on some variable annuity products and are also assumed from a ceding company; minimum investment return guarantees on insurance products offered in the Netherlands, including group pension and traditional products; variable annuities sold in Europe and Japan.

Since the price of these guarantees is not quoted in any market, the fair values of these guarantees are based on discounted cash flows calculated as the present value of future expected payments to policyholders less the present value of assessed rider fees attributable to the guarantees. Given the complexity and long-term nature of these guarantees which are unlike instruments available in financial markets, their fair values are determined by using stochastic models under a variety of market return scenarios. A variety of factors are considered including credit spread, expected market rates of return, equity and interest rate volatility, correlations of market returns, discount rates and actuarial assumptions. The most significant unobservable factor is discount rate. The credit spread used in the valuations of embedded derivatives in insurance contracts remained stable at 0.4% (December 31, 2016: 0.4%).

Unaudited

**Table of Contents**

22	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

The expected returns are based on risk-free rates. Aegon added a premium to reflect the credit spread as required. The credit spread is set by using the credit default swap (CDS) spreads of a reference portfolio of life insurance companies (including Aegon), adjusted to reflect the subordination of senior debt holders at the holding company level to the position of policyholders at the operating company level (who have priority in payments to other creditors). Aegon's assumptions are set by region to reflect differences in the valuation of the guarantee embedded in the insurance contracts.

Since many of the assumptions are unobservable and are considered to be significant inputs to the liability valuation, the liability included in future policy benefits has been reflected within Level III of the fair value hierarchy.

*Effect of reasonably possible alternative assumptions*

The effect of changes in unobservable inputs on fair value measurement were not significantly different than those that were applied to the consolidated financial statements as at and for the year ended December 31, 2016.

**Fair value information about financial instruments not measured at fair value**

The following table presents the carrying values and estimated fair values of financial assets and liabilities, excluding financial instruments which are carried at fair value on a recurring basis.

**Fair value information about financial instruments not measured at fair value**

<i>EUR millions</i>	Carrying amount March 31, 2017	Total estimated fair value March 31, 2017	Carrying amount December 31, 2016	Total estimated fair value December 31, 2016
<b>Assets</b>				
Mortgage loans - held at amortized cost	34,211	38,559	34,206	38,499
Private loans - held at amortized cost	3,230	3,592	3,166	3,569
Other loans - held at amortized cost	2,402	2,402	2,441	2,441
<b>Liabilities</b>				
Subordinated borrowings - held at amortized cost	768	866	767	844
	152	144	156	141

Trust pass-through securities - held  
at amortized cost

Borrowings - held at amortized cost	14,423	14,821	12,543	12,935
Investment contracts - held at amortized cost	17,494	17,874	19,217	19,748

[Financial instruments for which carrying value approximates fair value](#)

Certain financial instruments that are not carried at fair value are carried at amounts that approximate fair value, due to their short-term nature and generally negligible credit risk. These instruments include cash and cash equivalents, short-term receivables and accrued interest receivable, short-term liabilities, and accrued liabilities. These instruments are not included in the table above.

#### 14. Deferred expenses

<i>EUR millions</i>	Mar. 31, 2017	Dec. 31, 2016
Deferred policy acquisition costs (DPAC) for insurance contracts and investment contracts with discretionary participation features	10,901	10,882
Deferred cost of reinsurance	54	60
Deferred transaction costs for investment management services	481	481
<b>Total deferred expenses</b>	<b>11,435</b>	<b>11,423</b>

Unaudited

Table of Contents

Condensed Consolidated Interim Financial Statements 1Q 2017

23

**15. Intangible assets**

<i>EUR millions</i>	Mar. 31, 2017	Dec. 31, 2016
Goodwill	347	294
VOBA	1,338	1,399
Future servicing rights	62	64
Software	53	50
Other	41	12
<b>Total intangible assets</b>	<b>1,841</b>	<b>1,820</b>

Intangible assets, except for goodwill, are predominantly impacted by periodic amortization of balances and changes in foreign exchange rates. The acquisition of Cofunds Ltd. in January 2017 resulted in the addition of customer intangibles (included in the line Other ) amounting to EUR 29 million and goodwill amounting to EUR 56 million.

**16. Share capital**

<i>EUR millions</i>	Mar. 31, 2017	Dec. 31, 2016
Share capital - par value	319	319
Share premium	7,873	7,873
<b>Total share capital</b>	<b>8,193</b>	<b>8,193</b>
<b>Share capital - par value</b>		
Balance at January 1	319	328
Dividend	-	1
Shares withdrawn	-	(10)
<b>Balance</b>	<b>319</b>	<b>319</b>
<b>Share premium</b>		
Balance at January 1	7,873	8,059
Share dividend	-	(186)
<b>Balance</b>	<b>7,873</b>	<b>7,873</b>

*Basic and diluted earnings per share*



<i>EUR millions</i>	1Q 2017	1Q 2016
<b>Earnings per share</b> (EUR per share)		
Basic earnings per common share	0.17	0.05
Basic earnings per common share B	-	-
Diluted earnings per common share	0.17	0.05
Diluted earnings per common share B	-	-
<b>Earnings per share calculation</b>		
Net income / (loss) attributable to owners of Aegon N.V.	378	143
Coupons on other equity instruments	(35)	(35)
Earnings attributable to common shares and common shares B	343	109
Earnings attributable to common shareholders	341	108
Earnings attributable to common shareholders B	2	1
Weighted average number of common shares outstanding (in millions)	2,026	2,084
Weighted average number of common shares B outstanding (in millions)	568	585

Unaudited

**Table of Contents**

24	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

*Final dividend 2016*

It will be proposed to the Annual General Meeting of Shareholders on May 19, 2017, absent unforeseen circumstances, to pay a final dividend for the year 2016 of EUR 0.13 per common share. After taking into account the interim dividend 2016 of EUR 0.13 per common share, this will result in a total 2016 dividend of EUR 0.26 per common share. Proposed final dividend for the year and proposed total 2016 dividend per common share B amount to 1/40th of the dividend paid on common shares.

**17. Borrowings**

<i>EUR millions</i>	Mar. 31, 2017	Dec. 31, 2016
Capital funding	2,373	2,386
Operational funding	12,648	10,766
<b>Total borrowings</b>	<b>15,021</b>	<b>13,153</b>
Included in borrowings is EUR 598 million relating to borrowings measured at fair value (December 31, 2016: EUR 610 million).		

During the first three months of 2017, the operational funding increased EUR 1.8 billion due to new FHLB advances.

**18. Assets and Liabilities held for sale**

The major type of assets included in the assets held for sale comprise of the reinsurance asset linked to the sale of Aegon UK's annuity portfolio in 2016. The liability included in the liabilities held for sale are the insurance liabilities related to this portfolio. The UK annuity portfolio was included in the United Kingdom operating segment. For details related to the sale of the UK annuity portfolio, refer to the Annual Report 2016.

**19. Commitments and contingencies**

There have been no material changes in contingent assets and liabilities to those reported in the 2016 consolidated financial statements of Aegon.

**20. Acquisitions / divestments**

On January 1, 2017 Aegon completed the acquisition of Cofunds Ltd., following regulatory approval. The purchase of the Cofunds Ltd. business was done through a sale and purchase agreement to acquire all the shares and platform assets. The total consideration of the acquisition amounts to GBP 147 million (EUR 171 million). The fair value of the net assets amounts to GBP 99 million (EUR 116 million), of which GBP 25 million (EUR 29 million) relates to

customer intangibles, resulting in goodwill of GBP 48 million (EUR 56 million). The value of the transferred customer investments as per March 31, 2017 amounted to approximately GBP 87 billion (EUR 102 billion) and are not recognized on Aegon's balance sheet.

Unaudited

**Table of Contents****Condensed Consolidated Interim Financial Statements 1Q 2017****25**

To: The Supervisory Board and the Executive Board of Aegon N.V.

**Review report****Introduction**

We have reviewed the accompanying condensed consolidated interim financial statements for the three-month period ended March 31, 2017, of Aegon N.V., The Hague, as set out on pages 2 to 24, which comprises the condensed consolidated statement of financial position as at March 31, 2017, the condensed consolidated income statement, the condensed consolidated statement of comprehensive income, the condensed consolidated statement of changes in equity, the condensed consolidated cash flow statement and the selected explanatory notes for the three-month period then ended. Management is responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with IAS 34, *Interim Financial Reporting* as adopted by the European Union. Our responsibility is to express a conclusion on these condensed consolidated interim financial statements based on our review.

**Scope**

We conducted our review in accordance with Dutch law including standard 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Dutch auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

**Conclusion**

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements as at and for the three-month period ended March 31, 2017, are not prepared, in all material respects, in accordance with IAS 34, *Interim Financial Reporting* as adopted by the European Union.

Amsterdam, May 10, 2017

PricewaterhouseCoopers Accountants N.V.

Original has been signed by

R. Dekkers RA

Unaudited

**Table of Contents**

26	Condensed Consolidated Interim Financial Statements 1Q 2017
----	---

**Disclaimers****Cautionary note regarding non-IFRS-EU measures**

This document includes the following non-IFRS-EU financial measures: underlying earnings before tax, income tax and income before tax. These non-IFRS-EU measures are calculated by consolidating on a proportionate basis Aegon's joint ventures and associated companies. The reconciliation of these measures to the most comparable IFRS-EU measure is provided in note 3 Segment information of Aegon's Condensed Consolidated Interim Financial Statements. Aegon believes that these non-IFRS-EU measures, together with the IFRS-EU information, provide meaningful information about the underlying operating results of Aegon's business including insight into the financial measures that senior management uses in managing the business.

**Forward-looking statements**

The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:

- t Changes in general economic conditions, particularly in the United States, the Netherlands and the United Kingdom;
- t Changes in the performance of financial markets, including emerging markets, such as with regard to:
  - The frequency and severity of defaults by issuers in Aegon's fixed income investment portfolios;
  - The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and
  - The effects of declining creditworthiness of certain private sector securities and the resulting decline in the value of government exposure that Aegon holds;
- t Changes in the performance of Aegon's investment portfolio and decline in ratings of Aegon's counterparties;
- t Consequences of a potential (partial) break-up of the euro;
- t Consequences of the anticipated exit of the United Kingdom from the European Union;
- t The frequency and severity of insured loss events;
- t Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon's insurance products;

- t Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;
- t Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;
- t Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates;
- t Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;
- t Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets;
- t Changes in laws and regulations, particularly those affecting Aegon's operations, ability to hire and retain key personnel, taxation of Aegon companies, the products Aegon sells, and the attractiveness of certain products to its consumers;
- t Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates;
- t Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII);
- t Changes in customer behavior and public opinion in general related to, among other things, the type of products Aegon sells, including legal, regulatory or commercial necessity to meet changing customer expectations;
- t Acts of God, acts of terrorism, acts of war and pandemics;
- t Changes in the policies of central banks and/or governments;
- t Lowering of one or more of Aegon's debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon's ability to raise capital and on its liquidity and financial condition;
- t Lowering of one or more of insurer financial strength ratings of Aegon's insurance subsidiaries and the adverse impact such action may have on the premium writings, policy retention, profitability and liquidity of its insurance subsidiaries;
- t The effect of the European Union's Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;
- t Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;
- t As Aegon's operations support complex transactions and are highly dependent on the proper functioning of information technology, a computer system failure or security breach may disrupt Aegon's business, damage its reputation and adversely affect its results of operations, financial condition and cash flows;
- t Customer responsiveness to both new products and distribution channels;
- t Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon's products;
- t Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon's reported results and shareholders' equity;
- t Aegon's projected results are highly sensitive to complex mathematical models of financial markets, mortality, longevity, and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect, or should errors in those models escape the controls in place to detect them, future performance will vary from projected results;
- t The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon's ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;
- t Catastrophic events, either manmade or by nature, could result in material losses and significantly interrupt Aegon's business;
- t Aegon's failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess capital and leverage ratio management initiatives; and
- t This press release contains information that qualifies, or may qualify, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Unaudited



---

**Table of Contents**

Condensed Consolidated Interim Financial Statements 1Q 2017

Corporate and shareholder information

Headquarters

Aegon N.V.

P.O. Box 85

2501 CB The Hague

The Netherlands

+ 31 (0) 70 344 32

10

[aegon.com](http://aegon.com)

Group Corporate Communications & Investor Relations

Media relations

+ 31 (0) 70 344 89

56

[gcc@aegon.com](mailto:gcc@aegon.com)

Investor relations

+ 31 (0) 70 344 83

05

or 877 548 96 68 - toll free, USA only

[ir@aegon.com](mailto:ir@aegon.com)

Publication dates quarterly results 2017

August 10, 2017

Results second quarter 2017

November 9, 2017

Results third quarter 2017

February 15, 2018

Results fourth quarter 2017

Aegon's 1Q 2017 press release and Financial Supplement are available on [aegon.com](http://aegon.com).

About Aegon

Aegon's roots go back more than 170 years to the first half of the nineteenth century. Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world's leading financial services organizations, providing life insurance, pensions and asset management. Aegon's purpose is to help people achieve a lifetime of financial security. More information: [aegon.com](https://aegon.com).